Dexdor: a new hospital-only sedative

Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY
Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY

Dexdor (dexmedetomidine) is licensed for adult patients in intensive care who require sedation not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexmedetomidine is a selective alpha-2 receptor agonist. It exerts its sedative effect through decreased firing of the locus coeruleus, the predominant noradrenergic nucleus in the brainstem. Dexmedetomidine has minimal respiratory depressive effects.

Dexdor must be given by intravenous infusion using a controlled infusion device.

View Dexdor drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more